GlassScriptPhysician profile
Casey M Meeks
NPI 1013300045
$5,992.85
in general payments reported to CMS, 2019-2025
57 companies · $1,874 in 2025
The $1,874 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $325 · 2022: $690 · 2023: $2,152 · 2024: $953 · 2025: $1,874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,859 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,859.18 |
| Education | $118.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $860.50 | 2022-2025 | Tagrisso, Imfinzi, Enhertu |
| Novartis Pharmaceuticals Corporation | $404.76 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $388.42 | 2022-2025 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $317.75 | 2022-2025 | Opdivo, Opdualag, Augtyro |
| Genzyme Corporation | $279.24 | 2023-2025 | |
| Exelixis INC. | $247.72 | 2023-2025 | Cabometyx |
| Gilead Sciences, INC. | $234.15 | 2022-2025 | Trodelvy |
| Lilly USA, LLC | $213.23 | 2021-2025 | Retevmo, Verzenio, Jaypirca |
| Seagen INC. | $211.90 | 2021-2023 | Padcev, Tukysa |
| Eisai INC. | $194.24 | 2021-2025 | |
| Celgene Corporation | $187.70 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Incyte Corporation | $178.10 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| Merck Sharp & Dohme LLC | $148.95 | 2023-2025 | Keytruda, Lynparza, Reblozyl |
| Janssen Biotech, INC. | $138.97 | 2022-2025 | Erleada, Akeega, Balversa |
| Bayer Healthcare Pharmaceuticals INC. | $133.77 | 2024-2025 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Meeks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.